476 related articles for article (PubMed ID: 26842489)
1. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
[TBL] [Abstract][Full Text] [Related]
2. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
[TBL] [Abstract][Full Text] [Related]
3. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
[TBL] [Abstract][Full Text] [Related]
4. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
Bhagwandin SB; Naffouje S; Salti G
J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
[TBL] [Abstract][Full Text] [Related]
5. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
[TBL] [Abstract][Full Text] [Related]
6. Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies.
Dreznik Y; Hoffman A; Hamburger T; Ben-Yaacov A; Dux Y; Jacoby H; Berger Y; Nissan A; Gutman M
Surgeon; 2018 Oct; 16(5):278-282. PubMed ID: 29429947
[TBL] [Abstract][Full Text] [Related]
7. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
[TBL] [Abstract][Full Text] [Related]
8. Re-admissions for delayed complications after cytoreductive surgery and HIPEC.
Spiliotis J; Argiriou EO; Vafias E; Manou V; Vaos N; Datsis A; Efstathiou E
Acta Chir Belg; 2016 Apr; 116(2):96-100. PubMed ID: 27385296
[TBL] [Abstract][Full Text] [Related]
9. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
10. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
12. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score.
Malfroy S; Wallet F; Maucort-Boulch D; Chardonnal L; Sens N; Friggeri A; Passot G; Glehen O; Piriou V
Surg Oncol; 2016 Mar; 25(1):6-15. PubMed ID: 26979635
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
[TBL] [Abstract][Full Text] [Related]
14. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.
Simkens GA; van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2016 Jan; 23(1):99-105. PubMed ID: 26148758
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O
Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385
[TBL] [Abstract][Full Text] [Related]
16. Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
Kelly KJ; Cajas L; Baumgartner JM; Lowy AM
Ann Surg Oncol; 2018 Jan; 25(1):91-97. PubMed ID: 29090402
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
18. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
[TBL] [Abstract][Full Text] [Related]
19. Morbidity of the abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
Nunez MF; Sardi A; Nieroda C; Jimenez W; Sittig M; MacDonald R; Aydin N; Milovanov V; Gushchin V
Ann Surg Oncol; 2015 May; 22(5):1658-63. PubMed ID: 25245127
[TBL] [Abstract][Full Text] [Related]
20. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.
Ye J; Ren Y; Wei Z; Peng J; Chen C; Song W; Tan M; He Y; Yuan Y
Surg Oncol; 2018 Sep; 27(3):456-461. PubMed ID: 30217302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]